JP2022513111A5 - - Google Patents

Info

Publication number
JP2022513111A5
JP2022513111A5 JP2021528936A JP2021528936A JP2022513111A5 JP 2022513111 A5 JP2022513111 A5 JP 2022513111A5 JP 2021528936 A JP2021528936 A JP 2021528936A JP 2021528936 A JP2021528936 A JP 2021528936A JP 2022513111 A5 JP2022513111 A5 JP 2022513111A5
Authority
JP
Japan
Application number
JP2021528936A
Other languages
Japanese (ja)
Other versions
JP7707065B2 (ja
JPWO2020104649A5 (https=
JP2022513111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/082216 external-priority patent/WO2020104649A2/en
Publication of JP2022513111A publication Critical patent/JP2022513111A/ja
Publication of JP2022513111A5 publication Critical patent/JP2022513111A5/ja
Publication of JPWO2020104649A5 publication Critical patent/JPWO2020104649A5/ja
Application granted granted Critical
Publication of JP7707065B2 publication Critical patent/JP7707065B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021528936A 2018-11-23 2019-11-22 Angptl8を阻害するための新規のrna組成物および方法 Active JP7707065B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306562 2018-11-23
EP18306562.2 2018-11-23
PCT/EP2019/082216 WO2020104649A2 (en) 2018-11-23 2019-11-22 Novel rna compositions and methods for inhibiting angptl8

Publications (4)

Publication Number Publication Date
JP2022513111A JP2022513111A (ja) 2022-02-07
JP2022513111A5 true JP2022513111A5 (https=) 2022-11-29
JPWO2020104649A5 JPWO2020104649A5 (https=) 2022-11-29
JP7707065B2 JP7707065B2 (ja) 2025-07-14

Family

ID=64564803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021528936A Active JP7707065B2 (ja) 2018-11-23 2019-11-22 Angptl8を阻害するための新規のrna組成物および方法

Country Status (5)

Country Link
US (1) US12416004B2 (https=)
EP (1) EP3884051A2 (https=)
JP (1) JP7707065B2 (https=)
CN (1) CN113166760A (https=)
WO (1) WO2020104649A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3884051A2 (en) 2018-11-23 2021-09-29 Sanofi Novel rna compositions and methods for inhibiting angptl8
JP7667775B2 (ja) * 2019-09-05 2025-04-23 サノフイ ヌクレオチド類似体を含有するオリゴヌクレオチド
CA3224145A1 (en) 2021-06-24 2022-12-29 Melissa Ann Bellinger Novel rna therapeutics and uses thereof
WO2024138111A1 (en) 2022-12-23 2024-06-27 Eli Lilly And Company Novel rna therapeutics and uses thereof
CN118421622A (zh) * 2023-02-01 2024-08-02 北京福元医药股份有限公司 抑制血管生成素样蛋白8基因表达的siRNA、其缀合物和药物组合物及用途
WO2024227059A2 (en) * 2023-04-27 2024-10-31 Aligos Therapeutics, Inc. Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same
WO2025264952A2 (en) 2024-06-21 2025-12-26 Eli Lilly And Company Novel rna therapeutics and uses thereof
CN119367545B (zh) * 2025-01-02 2025-04-08 山东第一医科大学(山东省医学科学院) 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
WO2000003683A2 (en) 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
MXPA01003642A (es) 1998-10-09 2003-07-21 Ingene Inc Sintesis enzimatica de adnss.
BR9914773A (pt) 1998-10-09 2002-02-05 Ingene Inc Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
US8137695B2 (en) * 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ES2641272T3 (es) * 2006-04-28 2017-11-08 Children's Hospital Medical Center Composiciones que comprenden proteínas o polipéptidos fusogénicos derivados de la prosaposina para aplicación en sistemas de suministro de fármacos transmembrana
ES2428009T3 (es) * 2007-07-05 2013-11-05 Novartis Ag ARNds para tratar infecciones virales
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
AU2013299717B2 (en) * 2012-08-06 2018-06-28 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated RNA agents and process for their preparation
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
KR20180132843A (ko) * 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
EP3762395A1 (en) 2018-03-07 2021-01-13 Sanofi Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same
EP3884051A2 (en) 2018-11-23 2021-09-29 Sanofi Novel rna compositions and methods for inhibiting angptl8
US20220290156A1 (en) 2019-08-27 2022-09-15 Sanofi Compositions and methods for inhibiting pcsk9
JP7667775B2 (ja) 2019-09-05 2025-04-23 サノフイ ヌクレオチド類似体を含有するオリゴヌクレオチド
JP2023546103A (ja) 2020-10-16 2023-11-01 サノフイ Angptl3を阻害するための新規のrna組成物および方法
US20240035029A1 (en) 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
EP4232455A2 (en) 2020-10-20 2023-08-30 Sanofi Novel ligands for asialoglycoprotein receptor

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
JP2022513111A5 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)